Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

177Lu-octreotate

  • You have access
    Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
    Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin and Rodney J. Hicks
    Journal of Nuclear Medicine April 1, 2015, 56 (4) 505-511; DOI: https://doi.org/10.2967/jnumed.114.145581
  • You have access
    Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
    Samer Ezziddin, Mared Attassi, Charlotte J. Yong-Hing, Hojjat Ahmadzadehfar, Winfried Willinek, Frank Grünwald, Stefan Guhlke, Hans-Jürgen Biersack and Amir Sabet
    Journal of Nuclear Medicine February 1, 2014, 55 (2) 183-190; DOI: https://doi.org/10.2967/jnumed.113.125336
  • You have access
    Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
    Amir Sabet, Khaled Ezziddin, Ulrich-Frank Pape, Hojjat Ahmadzadehfar, Karin Mayer, Thorsten Pöppel, Stefan Guhlke, Hans-Jürgen Biersack and Samer Ezziddin
    Journal of Nuclear Medicine November 1, 2013, 54 (11) 1857-1861; DOI: https://doi.org/10.2967/jnumed.112.119347
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire